Quanterix Corporation has announced the publication of a new clinical study in JAMA Network Open, led by researchers at Amsterdam UMC, which followed a cohort of nearly 300 individuals for up to 15 years. The study demonstrated that combining multiple blood-based biomarkers—specifically amyloid, tau, neurodegeneration, and neuroinflammation—along with their longitudinal trajectories, provides a more comprehensive assessment of Alzheimer’s disease risk at the earliest stages compared to individual biomarkers alone. The study results have already been published and are accessible in the journal. Quanterix’s Simoa® technology and multiplexed biomarker assays were used in the study, and the company has introduced the LucentAD Complete test, which incorporates the same biomarkers evaluated in the research, offering an overall amyloid risk score and individual biomarker results for symptomatic individuals.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quanterix Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20260121870977) on January 21, 2026, and is solely responsible for the information contained therein.